Intuitive Surgical, Inc. $ISRG Stock: Axxcess Wealth Management LLC Reduces Position

Key Points

• Axxcess Wealth Management cut its Intuitive Surgical position by 88% in the third quarter, selling 8,547 shares and retaining 1,162 shares valued at approximately $473,000.
• Institutional investors remain heavily involved, collectively owning 83.64% of ISRG; several major funds, including Bank of America, Amundi, Arrowstreet Capital, and Janus Henderson, increased their holdings.
• Intuitive Surgical reported strong third-quarter results, with revenue rising 21.7% year over year to $3.05 billion and EPS beating estimates, while analysts maintained a generally positive outlook with a consensus “Moderate Buy” rating and a $493.54 average price target.

Axxcess Wealth Management LLC lowered its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 88.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,162 shares of the medical equipment provider's stock after selling 8,547 shares during the period. Axxcess Wealth Management LLC's holdings in Intuitive Surgical were worth $473,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ISRG. Bank of America Corp DE grew its holdings in Intuitive Surgical by 3.3% during the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider's stock valued at $1,667,388,000 after buying an additional 116,292 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Intuitive Surgical during the second quarter worth $1,335,753,000. Amundi raised its holdings in shares of Intuitive Surgical by 8.6% in the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider's stock worth $1,119,448,000 after acquiring an additional 193,096 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Intuitive Surgical by 95.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider's stock valued at $970,635,000 after purchasing an additional 1,027,475 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in Intuitive Surgical by 3.7% in the 1st quarter. Janus Henderson Group PLC now owns 1,643,060 shares of the medical equipment provider's stock valued at $757,489,000 after purchasing an additional 58,587 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Piper Sandler reissued an "overweight" rating on shares of Intuitive Surgical in a research note on Friday, August 21st. UBS Group reaffirmed a "buy" rating on shares of Intuitive Surgical in a research note on Tuesday, October 13th. Wall Street Zen cut shares of Intuitive Surgical from a "buy" rating to a "hold" rating in a research note on Sunday, September 20th. JPMorgan Chase & Co. boosted their price target on Intuitive Surgical from $450.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, October 21st. Finally, Truist Financial reduced their price target on Intuitive Surgical from $580.00 to $510.00 and set a "buy" rating on the stock in a research note on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Intuitive Surgical has a consensus rating of "Moderate Buy" and an average price target of $493.54.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical reported third-quarter revenue of approximately $3.05 billion, up more than 20% year over year, while earnings exceeded consensus expectations. The company also highlighted continued international expansion and adoption of its robotic-surgery systems. Intuitive Surgical Stock: Margin Hit Masks Strong Q3 Growth Story
• Positive Sentiment: Several firms remain constructive: BTIG, Stifel Nicolaus, Piper Sandler, and Oppenheimer reaffirmed or maintained Buy ratings. Baird also raised its price target, while Erste Group upgraded the stock to Buy. ISRG was added to the Zacks Rank #1 Strong Buy list. New Strong Buy Stocks for October 23rd
• Neutral Sentiment: The quarter included roughly $450 million of costs tied to an antitrust settlement, along with pricing-related pressure, which reduced margins. These items appear largely nonrecurring, but investors are assessing their effect on near-term profitability. Intuitive Surgical Reports Q3 2026 Earnings Impacted by $450M Antitrust Settlement
• Negative Sentiment: The key concern is that U.S. da Vinci procedure growth slowed to its lowest level since the COVID period. Investors worry that decelerating domestic demand could make it harder for Intuitive Surgical to sustain its premium valuation, which remains above 50 times earnings. Intuitive Surgical Sinks as U.S. da Vinci Growth Slows
• Negative Sentiment: RBC lowered its expectations for ISRG, and an analyst downgrade contributed to a gap lower in the shares. The market is emphasizing forward growth and valuation rather than the headline earnings beat. Intuitive Surgical Shares Gap Down Following Analyst Downgrade

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $452.29 on Monday. The company has a market cap of $156.78 billion, a P/E ratio of 54.69, a P/E/G ratio of 3.12 and a beta of 1.46. Intuitive Surgical, Inc. has a fifty-two week low of $328.57 and a fifty-two week high of $603.88. The firm's 50 day moving average is $395.50 and its two-hundred day moving average is $408.83.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The company had revenue of $3.05 billion during the quarter, compared to analysts' expectations of $2.91 billion. During the same period in the previous year, the company earned $2.40 EPS. The business's quarterly revenue was up 21.7% compared to the same quarter last year. Research analysts forecast that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In related news, EVP Mark Brosius sold 77 shares of Intuitive Surgical stock in a transaction on Friday, August 21st. The shares were sold at an average price of $375.57, for a total transaction of $28,918.89. Following the transaction, the executive vice president owned 881 shares in the company, valued at approximately $330,877.17. The trade was a 8.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the sale, the executive vice president directly owned 5,320 shares of the company's stock, valued at $2,016,280. The trade was a 6.99% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,342 shares of company stock valued at $4,882,357 over the last quarter. Company insiders own 0.60% of the company's stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company's primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.